Gilead Sciences (GILD) Getting Somewhat Positive Press Coverage, Study Finds
News stories about Gilead Sciences (NASDAQ:GILD) have been trending somewhat positive recently, Accern Sentiment reports. The research firm identifies positive and negative news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Gilead Sciences earned a news impact score of 0.20 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 46.734218899039 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Here are some of the news articles that may have effected Accern Sentiment Analysis’s analysis:
- J&J & Glaxo's Jucala Approval Puts Spotlight on HIV Space (finance.yahoo.com)
- Gilead: Attractive After Big Retreat? – Seeking Alpha (seekingalpha.com)
- Can Gilead Sciences Inc’s (GILD) ROE Continue To Surpass The Industry Average? (finance.yahoo.com)
- J&J & Glaxo Get FDA Approval for First Two-Drug HIV Regimen (finance.yahoo.com)
- Gilead: The Leader of the Pack…or Just Another Follower? (finance.yahoo.com)
Gilead Sciences (NASDAQ GILD) traded down $0.36 during midday trading on Friday, hitting $72.46. The stock had a trading volume of 2,335,914 shares, compared to its average volume of 9,288,879. The firm has a market cap of $95,122.51, a price-to-earnings ratio of 7.60, a P/E/G ratio of -1.22 and a beta of 1.13. Gilead Sciences has a fifty-two week low of $63.76 and a fifty-two week high of $86.27. The company has a quick ratio of 3.56, a current ratio of 3.68 and a debt-to-equity ratio of 1.10.
Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share for the quarter, beating the consensus estimate of $2.13 by $0.14. The business had revenue of $6.51 billion for the quarter, compared to analyst estimates of $6.40 billion. Gilead Sciences had a return on equity of 45.88% and a net margin of 41.65%. The company’s revenue was down 13.2% compared to the same quarter last year. During the same period in the previous year, the company posted $2.75 EPS. equities analysts expect that Gilead Sciences will post 8.53 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 28th. Stockholders of record on Friday, December 15th will be paid a $0.52 dividend. This represents a $2.08 annualized dividend and a dividend yield of 2.87%. The ex-dividend date is Thursday, December 14th. Gilead Sciences’s dividend payout ratio is currently 23.69%.
A number of analysts recently commented on the company. Argus cut Gilead Sciences from a “buy” rating to a “hold” rating and lifted their price objective for the stock from $73.25 to $73.77 in a research report on Monday, November 13th. Mizuho lifted their price objective on Gilead Sciences from $77.00 to $83.00 and gave the stock a “buy” rating in a research report on Wednesday, November 8th. Maxim Group reiterated a “hold” rating on shares of Gilead Sciences in a research report on Friday, October 27th. BMO Capital Markets dropped their price objective on Gilead Sciences from $89.00 to $83.00 and set an “outperform” rating for the company in a research report on Friday, October 27th. Finally, J P Morgan Chase & Co set a $85.00 price objective on Gilead Sciences and gave the stock a “buy” rating in a research report on Wednesday, October 25th. One investment analyst has rated the stock with a sell rating, twelve have assigned a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company. Gilead Sciences currently has an average rating of “Buy” and an average price target of $84.87.
In other news, insider John C. Martin sold 73,333 shares of Gilead Sciences stock in a transaction dated Friday, September 1st. The stock was sold at an average price of $83.11, for a total value of $6,094,705.63. Following the transaction, the insider now directly owns 2,996,766 shares of the company’s stock, valued at approximately $249,061,222.26. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Gregg H. Alton sold 15,000 shares of Gilead Sciences stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $74.82, for a total value of $1,122,300.00. Following the completion of the transaction, the executive vice president now directly owns 77,363 shares in the company, valued at $5,788,299.66. The disclosure for this sale can be found here. Insiders sold a total of 666,819 shares of company stock worth $52,303,086 over the last ninety days. Corporate insiders own 1.30% of the company’s stock.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.